Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar
Details : The purpose of the trial was to demonstrate the therapeutic equivalence in terms of efficacy between EG12014 to Herceptin®, and to compare the safety, immunogenicity and PK between the two trastuzumab products.
Product Name : EG12014
Product Type : Antibody
Upfront Cash : Inapplicable
March 23, 2021
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Poster Presentations to highlight the ongoing clinical studies targeting Globo H and AKR1C3 antigens in different tumor types.
Product Name : OBI-3424
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2020